Dr. Buckingham is a Professor in the Department of Pediatric Endocrinology at Stanford Medical Center and Stanford Children’s Hospital. His research focuses on continuous glucose monitoring in children and closed-loop (artificial pancreas) systems. He has been active as the principal investigator at Stanford in multiple NIH, JDRF and Helmsley sponsored research studies including DirecNet, TrialNet, the JDRF randomized clinical trial on continuous glucose monitoring, the JDRF closed-loop consortium, and multicenter Bionic Pancreas studies. He is currently doing closed-loop studies with Medtronic Diabetes, Type Zero, the University of Virginia, Insulet, Bigfoot Biomedical, Tandem, Animas, Rensselaer Polytechnic Institute, and Cambridge. His other interests include algorithms for detecting infusion set and sensor failures and to improve infusion set wear duration.

Dr. Russell is an Assistant Professor of Medicine at Harvard Medical School and an Attending Physician at Massachusetts General Hospital Diabetes Research Center. He completed medical and doctoral (MD/PhD) training at University of Texas Southwestern Medical School and a residency in Internal Medicine and fellowship in Endocrinology at the Massachusetts General Hospital. He is board certified in Endocrinology, Diabetes & Metabolism. Dr. Russell is a the principal clinical investigator of a collaboration between Massachusetts General Hospital and Boston University to develop a wearable bionic pancreas systems for automated glycemic management in people with diabetes mellitus. Dr. Russell’s other projects include evaluation of continuous glucose monitoring technology, methods for automated management of glucose in hospitalized patients, investigations of methods to improve insulin pharmacokinetics, investigations of stable formulations of glucagon, and development of a device for minimally invasive continuous insulin monitoring. Dr. Russell’s research has been supported by the National Institutes of Health (NIH), The Leona M. and Harry B. Helmsley Charitable Trust, the Banting Foundation, the American Diabetes Association, and the Juvenile Diabetes Research Foundation.

Edward Damiano, PhD, is Professor of Biomedical Engineering at Boston University. Ever since his son, David, developed type 1 diabetes as an infant over 17 years ago, he has set his sights on creating a bionic pancreas that David could take to college. He and his engineering team at BU began conducting experiments testing an early version of their bionic pancreas running on a laptop computer in diabetic pigs in 2005 and then progressed with their clinical collaborators at the Massachusetts General Hospital through in-patient trials in adults and adolescents with type 1 diabetes from 2008–2012. From 2013–2017, his team at BU and clinical collaborators have conducted seven outpatient clinical trials in adults and children with type 1 diabetes testing a mobile version of their bionic pancreas, which ran on an iPhone. He recently co-founded Beta Bionics, Inc., a Massachusetts Public Benefit Corporation, for the purpose of commercializing a fully integrated, wearable, bionic pancreas device that operates independently of a smartphone. Beta Bionics plans to ready this integrated device for clinical testing later this year and then conduct the final clinical trial testing the first commercial version of this device in the second half of next year.

Ahmad Haidar is an assistant professor in the Department of Biomedical Engineering, McGill University, Montreal, Canada. His research lies in applying control theory and Bayesian modeling to solve diabetes physiological and clinical problems, using a highly interdisciplinary bench-to-bedside approach. The development of the artificial pancreas is the current focus of his research.

Helen Murphy is a Professor of Womens Health at Kings College London and Professor of Medicine (Diabetes and Antenatal Care) at the University of East Anglia. She is also a practicing clinician at Cambridge University NHS Foundation Trust since 2006 and at Norfolk & Norwich University Hospital NHS Trust since 2015. She runs a diabetes pregnancy research programme which aims to improve the glucose control and infant health outcomes of pregnant women with diabetes. Her research interests include improving access to preconception care, developing novel continuous glucose monitoring and artificial pancreas technologies and the role of maternal dietary intake in gestational diabetes. She supervises higher degree students from diabetes & endocrinology, clinical biochemistry and obstetrics & gynaecology. Her research programme is funded by Juvenile Diabetes Research Foundation (JDRF), Diabetes UK, Diabetes Research & Wellness Foundation (DRWF), and the National Institute for Health Research (NIHR). She has led the regional East of England prepregnancy care projects, is a founding member of the National Pregnancy in Diabetes (NPID) audit and chair of the International Life Sciences Institute (ILSI) Gestational Diabetes Diet Group. She is regional editor for Diabetic Medicine, a member of the Diabetes UK scientific research committee and has previously served on the NIHR Health Technology Assessment Maternal and Child Health Board and the EU FP7 Grant Assessment Panel for Type 1 Diabetes.

Roman Hovorka is Director of Research at the Institute of Metabolic Science and Department of Paediatrics at University of Cambridge. He made seminal contributions to diabetes technology including the “Artificial Pancreas”, a device that delivers insulin in glucose responsive fashion. He is Chief Investigator on several trials evaluating the Artificial Pancreas in populations such as young children and newly diagnosed type 1 diabetes. His wider interests include mathematical modelling of glucose control and turnover.

Rich is an endocrinologist and Executive Director of the International Diabetes Center at Park Nicollet. In 2010 he was the ADA’s, President, Medicine & Science. In 2007, he was ADA’s Outstanding Physician Clinician. He serves on the steering committee of the 81 clinic T1D Exchange Clinic Registry. Dr. Bergenstal was Assistant Professor at the University of Chicago, where he received his MD and endocrinology training, before joining the IDC in 1983. He has served as a principal investigator for several NIH grants including, DCCT/EDIC (T1D), ACCORD & GRADE (T2D) and an NIDDK grant evaluating hybrid closed loop technology. Most of his career has centered on the importance of patient-centered team care and glucose pattern recognition. Two areas of recent focus include, standardizing glucose data reports utilizing the Ambulatory Glucose Profile (AGP) and effective strategies for implementing CGM and hybrid closed loop therapy into clinical practice. He teaches with the IDC team nationally and internationally on the importance of developing new models of care focused on achieving value in healthcare. He has been listed in Best Doctors in America since it began in 1992.